OMCL vs ZBH: fair value comparison
Omnicell, Inc. and Zimmer Biomet Holdings, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ZBH currently sits closer to the top of our discount ranking. OMCL carries the stronger quality grade.
| OMCL | ZBH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $34.51 | $93.49 |
| 12-month range | $29.96–$48.70 | $82.90–$100.56 |
| Sector rank | #42 of 113 Healthcare | #37 of 113 Healthcare |
| Quality grade | A | B |
| Momentum grade | — | B |
| Leverage | Low | Moderate |
| Margin trend | Stable | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | — |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: OMCL fair value analysis · ZBH fair value analysis